Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Molecular Cancer|August 17, 2017
Neutrophils in cancer: prognostic role and therapeutic strategiesAlberto Ocana, Cristina Nieto-Jiménez, Atanasio Pandiella, et al.
Nature Reviews. Clinical Oncology|February 2, 2010
Chemotherapy: dose-dense treatment for triple-negative breast cancerEitan Amir, Alberto Ocana, Orit Freedman, et al.
Journal of the National Cancer Institute|August 19, 2015
ResponseAlberto Ocana, Francisco Vera-Badillo, Arnoud Templeton, et al.
Mayo Clinic Proceedings|January 7, 2019
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Geroscience|September 27, 2025
Senescence-associated gene signatures predict survival in lung cancer: a multi-cohort analysisZoltán Ungvári, Otília Menyhart, Alberto Ocana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
Phase III trials of targeted anticancer therapies: redesigning the conceptAlberto Ocana, Eitan Amir, Francisco Vera-Badillo, et al.
Scientific Reports|December 14, 2017
Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancersJavier Perez-Peña, Verónica Corrales-Sánchez, Eitan Amir, et al.
Frontiers in Immunology|August 28, 2023
Considerations for the clinical development of immuno-oncology agents in cancerAtanasio Pandiella, Emiliano Calvo, Victor Moreno, et al.
Oncology|November 20, 2017
Reporting of Randomized Trials in Common Cancers in the Lay MediaDomen Ribnikar, Hadar Goldvaser, Alberto Ocana, et al.
Journal of the National Cancer Institute|December 11, 2012
HER3 overexpression and survival in solid tumors: a meta-analysisAlberto Ocana, Francisco Vera-Badillo, Bostjan Seruga, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Molecular Cancer|August 17, 2017
Neutrophils in cancer: prognostic role and therapeutic strategiesAlberto Ocana, Cristina Nieto-Jiménez, Atanasio Pandiella, et al.
Nature Reviews. Clinical Oncology|February 2, 2010
Chemotherapy: dose-dense treatment for triple-negative breast cancerEitan Amir, Alberto Ocana, Orit Freedman, et al.
Journal of the National Cancer Institute|August 19, 2015
ResponseAlberto Ocana, Francisco Vera-Badillo, Arnoud Templeton, et al.
Mayo Clinic Proceedings|January 7, 2019
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Geroscience|September 27, 2025
Senescence-associated gene signatures predict survival in lung cancer: a multi-cohort analysisZoltán Ungvári, Otília Menyhart, Alberto Ocana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
Phase III trials of targeted anticancer therapies: redesigning the conceptAlberto Ocana, Eitan Amir, Francisco Vera-Badillo, et al.
Scientific Reports|December 14, 2017
Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancersJavier Perez-Peña, Verónica Corrales-Sánchez, Eitan Amir, et al.
Frontiers in Immunology|August 28, 2023
Considerations for the clinical development of immuno-oncology agents in cancerAtanasio Pandiella, Emiliano Calvo, Victor Moreno, et al.
Oncology|November 20, 2017
Reporting of Randomized Trials in Common Cancers in the Lay MediaDomen Ribnikar, Hadar Goldvaser, Alberto Ocana, et al.
Journal of the National Cancer Institute|December 11, 2012
HER3 overexpression and survival in solid tumors: a meta-analysisAlberto Ocana, Francisco Vera-Badillo, Bostjan Seruga, et al.
Pageof 10